In mouse tumor models, researchers have found that combining node‐sparing radiotherapy and immunotherapy, PD‐L1 blockade targeting TDLN was enhanced by delivering progenitor‐type‐depleted T cells to the tumor site to enhance the anti‐tumor T‐cell immune response, thereby improving tumor control and mouse survival rate [31]. This evidence concerns the gene CD274 and neoplasm.